Navigation Links
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
Date:12/9/2007

- MGCD0103 Continues to Demonstrate Single-Agent Activity - 38% Response Rate, 43% Disease Control Rate and 86% Tumor Reduction Rate in Heavily-Pretreated Patients with Relapsed or Refractory Hodgkin Lymphoma

in 110mg Cohort - 67% Tumor Reduction Rate in Relapsed or Refractory Non-Hodgkin Lymphoma, Including an 18% Response Rate in Evaluable Diffuse Large B- cell Patients

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced data from two ongoing Phase 2 studies with MGCD0103, the Companies' novel, isotype-selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).

"These exploratory Phase 2 trials show meaningful activity of MGCD0103 in patients with differing types of lymphomas," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "This is important not only for the continuing development of MGCD0103 but also because it provides further evidence for the role of epigenetic therapies in the treatment of hematologic malignancies."

"Data from these most recent trials continue to demonstrate the single- agent potential for MGCD0103 in a patient population that currently has few effective therapeutic options," said Donald F. Corcoran, president and chief executive officer of MethylGene. "With our partners, we will continue to evaluate our current and near-term MGCD0103 clinical trials during 2008 with the goal to develop a potential registrational pathway."

Isotype Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin lymphoma (HL), Abstract #2566 (Trial 010)

To date, 33 patients
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... GLASSBORO, N.J., Aug. 25 Getting a firmer, healthier, better-looking body -- in ... a fitness plan that will truly help you reach your personal goals. , ... , , , An ... you will dedicate to achieving your fitness goals and stick with it! , ...
... , Study Suggests Division, Ambivalence and Hesitancy ... ANN ARBOR, Mich., Aug. 25 Americans lack confidence that healthcare ... to a survey released today by the Thomson Reuters. , ... healthcare reform, addresses a wide range of issues including the cost ...
... Most OTC hemorrhoid ... your hemorrhoids faster. , ... York, NY (PRWEB) August 26, 2009 -- Many drug companies desperately do not want revealed ... damage. "Steroid creams in particular may cause permanent damage or ulceration of perianal skin," states ...
... , , Updated Report ... , , LANDOVER, Md., Aug. 25 ... conditions, the school-house is a focal point for managing their diseases. ... and Allergy Foundation of America (AAFA) has released a report assessing ...
... ONCOLOGY: Human breast cancer hit for six: key role for ... and colleagues, at the University of Colorado School of Medicine, ... mouse models and analysis of human cells, implicating the protein ... that plays a central role in development, is not expressed ...
... , , OMAHA, ... its private equity sponsor, Diamond Castle Holdings and the Company,s Management ... debt and renegotiated favorable new terms and conditions with its banking ... As a result of this transaction, overall debt for YORK ...
Cached Medicine News:Health News:Why Weight for a Better Body? 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 3Health News:JCI table of contents: Aug. 24, 2009 2Health News:JCI table of contents: Aug. 24, 2009 3Health News:JCI table of contents: Aug. 24, 2009 4Health News:JCI table of contents: Aug. 24, 2009 5Health News:JCI table of contents: Aug. 24, 2009 6Health News:YORK Label Announces Continued Investment in the Company 2
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Foley Catheters (Latex) 2-Way...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Medicine Products: